METHODS COMPRISING DESMOPRESSIN
First Claim
Patent Images
1. A method for increasing an initial period of undisturbed sleep in a patient in need thereof comprising:
- administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period increases the patient'"'"'s initial period of undisturbed sleep.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.
-
Citations
140 Claims
-
1. A method for increasing an initial period of undisturbed sleep in a patient in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period increases the patient'"'"'s initial period of undisturbed sleep.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A method for reducing nocturnal urine volume in a patient in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal urine volume.- View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19)
-
20. A method for reducing nocturnal voids in a female patient in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal voids.- View Dependent Claims (21, 22, 23, 24, 25, 26, 27)
-
28. A method for increasing an initial period of undisturbed sleep in a female patient in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period increases the patient'"'"'s initial period of undisturbed sleep.- View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)
-
40. A method for reducing nocturnal urine volume in a female patient in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal urine volume.- View Dependent Claims (41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)
-
52. A method for reducing nocturnal voids in a female patient above 50 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal voids.- View Dependent Claims (53, 54, 55, 56, 57, 58, 59)
-
60. A method for increasing an initial period of undisturbed sleep in a female patient above 50 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period increases the patient'"'"'s initial period of undisturbed sleep.- View Dependent Claims (61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)
-
73. A method for reducing nocturnal urine volume in a female patient above 50 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 μ
g or 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal urine volume.- View Dependent Claims (74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)
-
85. A method for reducing nocturnal voids in a female patient above 65 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal voids.- View Dependent Claims (86, 87, 88, 89, 90, 91, 92)
-
93. A method for increasing an initial period of undisturbed sleep in a female patient above 65 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period increases the patient'"'"'s initial period of undisturbed sleep.- View Dependent Claims (94, 95, 96, 97, 98, 99, 100, 101, 102)
-
103. A method for reducing nocturnal urine volume in a female patient above 65 years of age in need thereof comprising:
administering to the patient prior to bedtime an orodispersible dose of desmopressin of 25 μ
g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient'"'"'s nocturnal urine volume.- View Dependent Claims (104, 105, 106, 107, 108, 109, 110, 111, 112, 113)
-
114. A method for reducing nocturnal urine volume in a male patient in need thereof comprising:
-
measuring the patient'"'"'s serum sodium level; administering to the patient, with a serum sodium level of at least 135 mmol/L, prior to bedtime an orodispersible dose of desmopressin of 100 μ
g, wherein the dose is measured as the free base of desmopressin;measuring the patient'"'"'s serum sodium level at a time interval after administration; continuing the administration of the dose of desmopressin with the patient having at least 130 mmol/L serum sodium level; wherein the dose administered over a treatment period reduces the patient'"'"'s nocturnal urine volume. - View Dependent Claims (115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)
-
-
129. A method of treating nocturia comprising administering sublingually to a subject in need thereof a dose of desmopressin, wherein the dose is measured as the free base and is selected from the group consisting of 10 μ
- g, 25 μ
g, 50 μ
g, and 100 μ
g of desmopressin daily. - View Dependent Claims (130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)
- g, 25 μ
Specification